Small Stocks, Big Money

In our exclusive interview, John Passalacqua, CEO & Director of First Phosphate, explains why First Phosphate ($FRSPF | CSE: PHOS) is positioning itself as a critical North American supplier to the fast-growing LFP battery market.Key topics from the interview include:• A $16.7 million non-dilutive contribution from the Government of Canada, helping advance feasibility work and key process validation without additional equity dilution, according to management.• Why igneous phosphate matters for battery applications, including its high purity and potential efficiency in conversion to battery-grade phosphate for LFP batteries.• First Phosphate’s vertically integrated strategy, spanning phosphate rock, concentrate, purified phosphoric acid, iron phosphate precursor, cathode active material, and LFP battery cells, as shown in the value chain graphic on page 2 of the fact sheet.• Commercial traction, including management commentary on a definitive bankable offtake agreement and prepayment from a European partner.• Scale potential supported by an advanced resource of approximately 255 million tonnes and a Preliminary Economic Assessment highlighting ~900,000 tonnes per year of phosphate concentrate, ~CAD $2.1B NPV, ~37% IRR, and ~3-year payback.• Why management believes phosphate is the overlooked input in LFP batteries, with phosphate representing a major share of cathode mass.👉 First Phosphate is a client of RedChip. Visit https://www.FRSPFinfo.com to learn more and sign up for news alerts.#FRSPF #PHOS #FirstPhosphate #LFPBatteries #BatteryMaterials #CriticalMinerals #EnergyStorage #EVStocks #SmallCapStocks #MicroCapStocks #InvestorInterview

This week's episode of Small Stocks Big Money features exclusive interviews with senior executives from Enlivex Therapeutics Ltd. (NASDAQ: ENLV) & Off The Hook Inc. (NYSE American: OTH)Explore the latest insights and updates in the world of small-cap stocks.Visit RedChip.com to learn more.

In our exclusive interview, Jay Hatfield (Founder, CEO, and Portfolio Manager at InfraCap) outlines a disciplined approach to small-cap investing built around profitability, valuation, and income generation and discusses the opportunity set for small caps as macro conditions evolve.Jay breaks down the portfolio construction behind InfraCap Small Cap Income Fund (NYSE: SCAP), designed to target 7%+ yield by focusing on profitable, dividend-paying companies, selective preferred exposure, and measured options activity.Key topics we covered:• SCAP’s mandate and portfolio filters: why profitability is non-negotiable in small caps• Income-first small caps: combining dividend payers with preferreds and selective call writing• Risk management lessons: avoiding the “blowups” that drive long-term underperformance• Valuation discipline: using PEG / PEGY (growth + yield) to prevent overpaying• Small-cap setup: why undercoverage and depressed relative valuations can create opportunity• Macro watchlist: why core PCE inflation is the key input for Fed policy and small-cap momentumSmall caps remain an under-researched segment of the market. Jay's process emphasizes repeatable underwriting, downside control, and income as a contributor to total return, particularly in environments where rate expectations and inflation data can shift sentiment quickly.#Investing #SmallCaps #IncomeInvesting #Dividends #PreferredStocks #Macro #FederalReserve #SCAPThis post contains sponsored content. This content is for informational purposes only and is not intended to be investment advice. The opinions RedChip expresses are solely their own and are not the opinions of Infrastructure Capital Advisors, LLC, nor its affiliates. The opinions expressed are for information purposes only and do not constitute an offer to buy or sell securities, options, or cryptocurrency. Please conduct your own research and consult your own tax attorney or financial advisor before making an investment decision. The information in this video and the corresponding websites is neither an offer nor a recommendation to buy or sell any security, options on equities, or cryptocurrency. Past performance is not necessarily indicative of future results. No trading strategy is risk-free. Trading and investing involve substantial risk, and you may lose the entire amount of your principal investment or more. You should trade or invest only “risk capital” – money you can afford to lose. ICA has not been involved in the preparation of the content supplied at these websites, and does not endorse these websites, their sponsors, or any of the policies, products, activities, or services offered on the sites. The content is provided, “as is”, without representation or warranty, express or implied, as to their accuracy, completeness, or timeliness of such content, all of which ICA disclaims. This is not financial advice, and returns are not guaranteed. Do your own due diligence before investing.

Watch our replay of Enlivex’s FY25 Financial Results Webcast to hear management discuss the company’s outlook, financial performance, and its differentiated dual strategy combining quality longevity therapeutics with a prediction markets treasury model.Key FY2025 Highlights:• Net income of $1.23 billion• Diluted EPS of $25.48• Total treasury and treasury-related derivative assets of $2.31 billion• Shareholders’ equity of $1.93 billion• $30.0 million in cash, cash equivalents, and short-term investments in digital assetsEnlivex is positioning itself as a public market vehicle with exposure to two high-interest themes:• Quality longevity therapeutics, led by Allocetra™ and its focus on inflammatory conditions associated with aging• Prediction markets infrastructure, through treasury exposure tied to the RAIN protocol👉 Enlivex is a client of RedChip. Visit https://www.ENLVinfo.com to learn more and sign up for news alerts.#ENLV #Enlivex #Nasdaq #SmallCapStocks #MicroCapStocks #BiotechStocks #GrowthStocks #StockMarket #InvestorUpdate #Earnings #HealthcareStocks #Longevity #DigitalAssets

Enlivex (Nasdaq: ENLV) CEO Oren Hershkovitz breaks down the company’s two-pillar strategy designed to build shareholder value through both biotech execution and balance sheet strategy.Pillar 1: Clinical Development (AllocetraTM)Enlivex is advancing its immunotherapy platform with a focus on knee osteoarthritis, a large and growing market with limited effective treatment options. In the interview, management discusses durable, statistically significant results in an older, underserved OA population and the roadmap toward later-stage clinical development.Pillar 2: Digital Asset Treasury Management (Prediction Markets via RAIN)Enlivex is also pursuing a treasury strategy centered on prediction markets, with exposure to the RAIN token. The CEO outlines why the company believes event-driven markets are scaling rapidly, why being an early mover could matter, and how treasury gains and yield could be used to both expand the treasury position and support accelerated clinical development.How the two pillars connectThe core thesis is a dual-engine approach: potential value creation from late-stage clinical catalysts on one side, paired with a treasury strategy intended to generate incremental upside and potentially support funding needs on the other, aiming to reduce reliance on dilution while maintaining momentum in the pipeline.Topics covered:• Why Enlivex believes its two pillars can work together to drive shareholder value• Knee osteoarthritis focus and why age-related patients matter medically and commercially• The RAIN treasury strategy, optionality, and what management sees as the long-term upside• What investors should watch next and the timeline discussed in the interview👉 Enlivex is a client of RedChip. To learn more about ENLV and to read our full disclosure, visit: https://www.ENLVinfo.com#ENLV #SmallCapStocks #BiotechStocks #NASDAQ #Osteoarthritis #ClinicalTrials #InvestorInterview #MicroCapStocks

Off The Hook (NYSE American: OTH) CEO Brian John joins us for an exclusive interview to break down what makes OTH different from a traditional boat dealer and why management believes the company is entering a major growth phase.In our conversation, Brian explains how Off The Hook’s AI-powered platform helps price and move used boats with speed and accuracy, positioning the company as a high-velocity marine liquidity platform in the fragmented U.S. used boat market. The company says it generated approximately $82.6 million in revenue in the first nine months of 2025, delivered about $99 million in FY2024 revenue, and has guided to $140 million to $145 million in FY2026 revenue, excluding the expected impact of the Apex acquisition and post-IPO floorplan expansion.Off The Hook is pitching a differentiated model built around used boat liquidity, vertical integration, and margin capture across sourcing, brokerage, auctions, financing, warranty, and insurance.👉 Off The Hook is a client of RedChip. To learn more about OTH and to read our full disclosure, visit: https://www.redchip.com/stocks/OTH#OTH #OffTheHook #NYSEAmerican #SmallCapStocks #StockMarket #GrowthStocks #InvestorInterview #BrianJohn #BoatingIndustry #AIStocks

What makes Comprehensive Healthcare Systems (OTCQB: CMHSF | TSXV: CHS) a story investors should be watching right now?In our exclusive interview, Chris Cosgrove, President & CEO of Comprehensive Healthcare Systems, breaks down how the company is building a scalable healthcare SaaS platform designed to automate complex benefits administration for unions, self-insured employers, third-party administrators, and government clients.CHS' proprietary Novus 360 platform is built to replace fragmented legacy systems with an integrated solution for eligibility, claims processing, pension administration, compliance, and member engagement. The company is targeting a large U.S. healthcare benefits administration software market estimated at $4B to $6B annually, while already supporting more than 1 million members and processing over $1.8B in healthcare claims.In our interview, Chris discusses:• Why CHS’s position in the government-mandated Taft-Hartley market creates a potential competitive moat• How Novus 360 can automate up to 85% of claims adjudication and improve workflow efficiency• Why the company believes it can scale through both organic growth and acquisitions• Annualized recurring revenue targets of about $10M by year-end 2026, with expected gross margins of 65% to 70% and EBITDA margins of 10% to 15%• The path from approximately US$25M in signed contracts today toward a US$100M contract target by 2028For investors looking at underfollowed healthcare technology and small-cap SaaS opportunities, this interview offers insight into CHS’s strategy, operating leverage potential, and growth roadmap.👉 Comprehensive Healthcare Systems is a client of RedChip. To learn more about CMHSF and to read our full disclosure, visit: https://www.redchip.com/stocks/CMHSF#CMHSF #CHS #OTCQB #TSXV #SmallCapStocks #HealthcareStocks #SaaSStocks #GrowthStocks #StockMarket #Investing #HealthcareTechnology

​ @themetalscompany (Nasdaq: TMC) is a developer of lower-impact critical metals from seafloor polymetallic nodules, on a dual mission: (1) supply metals for energy, defense, manufacturing and infrastructure with net positive impacts compared to conventional production routes and (2) trace, recover and recycle the metals we supply to help create a metal commons that can be used in perpetuity. The Company has conducted more than a decade of research into the environmental and social impacts of offshore nodule collection and onshore processing. More information is available at www.metals.co.Visit Metals.co to learn more.

BioVie (Nasdaq: BIVI) President and CEO Cuong Do joins us for an exclusive investor interview discussing BioVie’s late-clinical-stage pipeline and upcoming milestones across neurodegeneration and liver disease.In our conversation, Cuong outlines why BioVie is targeting TNFα-mediated inflammation and insulin resistance with bezisterim (formerly NE3107), plus the company’s second program, BIV201, for refractory ascites, a high-mortality complication of liver cirrhosis with no FDA-approved drug therapies today.BioVie is positioning for multiple catalysts across a differentiated clinical-stage portfolio targeting large unmet needs in neurodegeneration and liver disease, supported by an experienced leadership team.Watch the full interview for management’s full roadmap, trial design insights, and how the company is thinking about value creation over the next 12 months.👉 BioVie is a client of RedChip. To learn more about BIVI and to read our full disclosure, visit: https://www.BIVIinfo.com#BIVI #BioVie #BiotechStocks #SmallCapStocks #Investing #Parkinsons #LongCOVID #Alzheimers #ClinicalTrials #HealthcareInvesting

Lithium iron phosphate (LFP) batteries now power the majority of global battery production, but supply chains remain heavily concentrated in Asia. In our exclusive interview, First Phosphate (OTCQX: FRSPF | CSE: PHOS | FSE: KD0) CEO John Passalacqua explains how the company is working to onshore a full North American LFP supply chain, starting with high-purity igneous phosphate in Quebec and progressing downstream toward battery materials.Phosphate is a critical, heavy-by-mass input in LFP cathodes, so securing a North American supply becomes more important as demand grows across energy storage, data centers, and AI infrastructure. First Phosphate highlights its Quebec igneous phosphate as a potential advantage because higher-purity, low-contaminant feedstock can translate into more efficient production of battery-grade purified phosphoric acid versus many sedimentary sources.👉 First Phosphate is a client of RedChip. To learn more about FRSPF and to read our full disclosure, visit: https://www.FRSPFinfo.com#FRSPF #PHOS #BatteryMetals #LFP #EnergyStorage #CriticalMinerals #SmallCapStocks #MicroCapInvesting

In our investor-focused interview, Mark White, CEO of Nexalin Technology (Nasdaq: NXL), breaks down how the company is building a non-invasive neurostimulation platform aimed at major unmet needs across brain health, including depression, insomnia, PTSD/TBI, and Alzheimer’s/dementia.Nexalin’s mission is to lead what it calls the “brain health movement” with treatment designed to be safe, effective, and drug-free, supported by a growing body of peer-reviewed research and a roadmap centered on Mood, Military, and Memory.Nexalin’s edge is its frequency-based approach designed to emulate natural brain activity through Deep Intracranial Frequency Stimulation (DIFS™). Clinical validation includes peer-reviewed results published in Radiology showing improved cognition and stronger brain network connectivity in mild Alzheimer’s disease. Additional peer-reviewed findings point to broader potential, including blood pressure reduction in depression (Journal of Affective Disorders) and improved attention with normalized brain activity in ADHD (Molecular Psychiatry).👉 Nexalin Technology is a client of RedChip. To learn more about NXL and to read our full disclosure, visit: https://www.NXLinfo.com#NXL #Nexalin #Nasdaq #SmallCapStocks #MicroCapStocks #StockMarket #GrowthStocks #BiotechStocks #MedTech #DigitalHealth #MedicalDevices #Neurostimulation

Darren Wang, Founder, Chairman, and CEO of OBOOK Holdings (Nasdaq: OWLS), joins us to discuss how OwlTing is building a compliance-first stablecoin and fiat payment infrastructure for global commerce, as well as what investors should watch in 2026.In our interview, Darren explains why stablecoins are moving beyond speculation into real-world settlement, how OwlPay supports enterprise-scale integrations, and how OWLS is positioning for utilization-driven growth as global payment rails modernize.OWLS is targeting a massive and growing global payments market, with company materials citing global payments revenue above $2.5T in 2024 and projected to exceed $3.0T by 2029, while stablecoins and cross-border settlement are among the fastest-growing segments.👉 OBOOK Holdings is a client of RedChip. To learn more about OWLS and to read our full disclosure, visit: https://www.OWLSinfo.com #Fintech #Stablecoins #Payments #Nasdaq #TechInvesting #OWLS

NioCorp (Nasdaq: NB) CEO Mark Smith joins us to break down a milestone year for the Elk Creek Critical Minerals Project in Nebraska and what could be next for U.S. onshoring of niobium, scandium, and magnetic rare earths.NioCorp is positioning Elk Creek as a construction-ready, fully permitted U.S. critical minerals project with long-duration potential and exposure to national security and next-gen manufacturing demand. Company materials highlight: 75% of planned niobium output under long-term offtake agreements, a DoD Title III grant up to $10M for a domestic scandium mine-to-metal supply chain, and Ex-Im processing of up to ~$780M in potential project financing.👉 NioCorp is a client of RedChip. To learn more about NB and to read our full disclosure, visit: https://www.NioCorpinfo.com #NioCorp #NB #CriticalMinerals #Niobium #Scandium #RareEarths #MiningStocks #MetalsInvesting #EnergyTransition #DefenseTech #SmallCapStocks

Join @RedChip for an investor Q&A webinar with ASP Isotopes (Nasdaq: ASPI) Executive Chairman and CEO Paul Mann, covering ASPI’s transition into commercial isotope production and its strategy at the intersection of clean energy, advanced semiconductors, and nuclear medicine.In our session, Paul addresses timelines for revenue-generating isotope shipments, updates on key facilities, capital position, and funding plans, as well as how ASPI’s partnerships could support long-term HALEU demand for next-generation nuclear reactors.ASP Isotopes is advancing proprietary isotope enrichment platforms supporting high-value end markets, including semiconductors (Silicon 28), nuclear medicine (including Yb-176 and other pipeline targets), and clean energy via HALEU supply initiatives. The company highlights definitive agreements with TerraPower for HALEU supply and financing, a joint venture with Fermi America for a U.S. enrichment presence, and a pending acquisition of Renergen to expand into helium and LNG.👉 ASP Isotopes is a client of RedChip. To learn more about ASPI and to read our full disclosure, visit: https://www.ASPIinfo.com #ASPI #Investing #SmallCapStocks #NuclearEnergy #HALEU #SMR #TerraPower #Semiconductors #Isotopes #QuantumComputing #NuclearMedicine #CleanEnergy #EnergyInvesting #TechInvesting

In our in-depth interview, Scott Monteith, CEO of Avalon Advanced Materials (OTCQB: AVLNF), breaks down why Avalon is emerging as one of North America’s most strategically positioned critical minerals companies.🔗 Avalon Advanced Materials is a client of RedChip. To learn more about AVLNF and to read our full disclosure, visit: AVLNFinfo.com.#AVLNF #LithiumStocks #RareEarthStocks #CriticalMinerals #SmallCapStocks #EVSupplyChain #CleanEnergyInvesting #StockInterviews #InvestorEducation

In this exclusive interview, Bruce Ogilvie, Executive Chairman of Alliance Entertainment (NASDAQ: AENT), outlines the company’s strategy to drive sustainable earnings growth across physical media, collectibles, and exclusive licensed content.Alliance Entertainment sits at the center of the global entertainment and collectibles ecosystem, distributing over 340,000 SKUs across vinyl, film, video games, toys, and pop culture collectibles to 35,000+ retail storefronts and 200+ e-commerce platforms. In this discussion, Ogilvie explains how Alliance’s capital-light fulfillment model, deep industry expertise, and exclusive studio relationships are creating durable competitive advantages.Key Topics Covered:• Drivers behind Alliance’s double-digit revenue growth entering fiscal 2026• Expansion of exclusive licensing agreements, including Paramount Home Entertainment• How $250M+ in trailing revenue from exclusive content builds a defensible moat• The strategic importance of Handmade by Robots, Alliance’s proprietary collectibles IP• Margin expansion driven by automation, product mix, and direct-to-consumer fulfillment• Management’s outlook for meaningful EPS growth, with earnings projected to nearly double year over yearWith physical collectibles, vinyl, and premium media formats showing renewed demand, Alliance is leveraging scale, exclusivity, and intellectual property ownership to transition toward higher-margin revenue streams while maintaining strong cash flow and balance sheet discipline.👉 Alliance Entertainment is a client of RedChip. To learn more about AENT and to read our full disclosure, visit: AENTinfo.com.#AENT #AllianceEntertainment #SmallCapStocks #InvestorInterview #StockMarketInvesting #EntertainmentStocks #MediaStocks #CollectiblesMarket #LicensingRevenue #EarningsGrowth #NASDAQStocks #ValueInvesting #GrowthStocks #WallStreet #InstitutionalInvestors #RetailInvestors #PhysicalMedia #VinylRecords #PopCultureCollectibles

In this exclusive interview, David Young, PhD, President of Research & Development and Founder of Processa Pharmaceuticals (Nasdaq: PCSA), breaks down the latest Phase 2 clinical progress for the company’s lead oncology program targeting advanced breast cancer.🔬 Key Topics We Covered:• Positive preliminary Phase 2 data from the oral combination therapy PCS6422 + capecitabine• Evidence showing ~10x increase in cancer-killing metabolites while maintaining similar side effect severity versus standard capecitabine• How Processa’s approach aims to improve efficacy without increasing toxicity• Details on the formal 20-patient interim analysis evaluating safety and efficacy, expected in 2026• How this program could potentially replace current capecitabine monotherapy in certain breast cancer settings• Insights into the FDA development pathway and dose optimization ahead of a potential pivotal trial🎯 David Young brings over 40 years of experience in chemotherapy drug development, including deep expertise in 5-FU and capecitabine metabolism, which uniquely positions him to lead Processa’s clinical innovation.👉 Processa Pharmaceuticals is a client of RedChip. To learn more about PCSA and to read our full disclosure, visit: PCSAinfo.com.#ProcessaPharmaceuticals #PCSA #BiotechStocks #SmallCapStocks #Oncology #BreastCancerResearch #ClinicalTrials #Phase2Trial #CancerTherapeutics #BiotechInvesting #HealthcareStocks #NASDAQStocks #DrugDevelopment #FDAApproval #LifeSciences #GrowthStocks #InvestorInterview

In this exclusive interview, E. Will Gray II, Chairman, CEO, and Interim CFO of New Era Energy & Digital (Nasdaq: NUAI), breaks down the company’s strategy to become a critical player in AI data center infrastructure and power generation.New Era Energy & Digital is developing large scale, powered data center sites in the Permian Basin, leveraging behind the meter natural gas, future nuclear capacity, and renewable energy to meet surging demand from AI, cloud computing, and high performance computing workloads.With global spending on AI infrastructure projected to reach trillions of dollars over the next decade, NUAI is positioning itself at the intersection of energy security and digital transformation.📌 Speed to power, land availability, and cost efficiency are becoming the most critical constraints for AI data center growth. New Era Energy & Digital aims to solve these challenges with scalable, power ready sites in one of the most resource rich regions in the U.S.👉 New Era Energy & Digital is a client of RedChip. To learn more about NUAI and to read our full disclosure, visit: NUAIinfo.com.#NUAI #AIInfrastructure #DataCenters #EnergyStocks #GrowthStocks #AIInvesting #DigitalInfrastructure #InvestorInterview

In our in-depth interview, NioCorp (Nasdaq: NB) CEO Mark Smith discusses the rapidly evolving landscape for U.S. critical minerals and the company’s progress toward construction of its Elk Creek Project in Nebraska. Investors will gain insight into supply chain pressures, heavy rare earth export dynamics, and the rising strategic importance of niobium, scandium, and rare earth elements in defense and clean energy markets.🎯 Key Topics We Covered• Current global constraints impacting U.S. access to heavy rare earths• How investors should evaluate critical mineral projects using feasibility, metallurgy, permitting, and resource validation• Details on NioCorp’s collaboration with Lockheed Martin Skunk Works to advance scandium aluminum alloy technologies• Update on more than $370M raised year to date and progress with the U.S. Export Import Bank on potential project debt financing• Engineering, drilling, and site preparation milestones that position NioCorp for construction readiness📌 Why This Matters for Investors:• NioCorp is advancing one of North America’s largest critical mineral resources with all major permits secured, tier one offtake agreements in place, and growing engagement from defense and industrial end users. The company’s emphasis on feasibility-level engineering, customer-qualified metallurgy, and project financing advancement provides a clearer roadmap toward potential production.Learn more about NioCorp and the Elk Creek Project in our exclusive investor-focused conversation.NioCorp is a client of RedChip. To learn more about NB and to read our full disclosure, visit: NioCorpinfo.com.#NioCorp #NB #CriticalMinerals #RareEarths #Scandium #Niobium #DefenseIndustry #Investing #SmallCapStocks #MiningIndustry #ProjectFinancing

📌 In our exclusive interview, Nova Minerals (Nasdaq: NVA) CEO Chris Gerteisen breaks down the company’s rapid transformation into a U.S. critical minerals and gold development leader. With a $43.4 million Defense Production Act award from the U.S. Department of War, Nova is advancing toward military-grade antimony production by 2026/27 — positioning itself as the first fully integrated domestic supplier in decades.Nova’s Estelle Project in Alaska sits on a 35 km mineralized corridor hosting one of North America’s largest undeveloped gold systems, including a 5.2Moz SK-1300 pit-constrained resource. Chris discusses how the company’s latest world-class drill intercepts support strong project economics and why Nova still trades at a steep valuation discount relative to peers.👉 If you found this interview valuable, make sure to like the video, drop a comment with your thoughts or questions, and subscribe for more in-depth conversations with CEOs from emerging small-cap and microcap companies!Nova Minerals is a client of RedChip. To learn more about NVA and to read our full disclosure, visit: NVAinfo.com.#NovaMinerals #NVA #GoldStocks #CriticalMinerals #Antimony #MiningStocks #SmallCapStocks #GoldInvesting #AlaskaMining #DefenseProductionAct #USCriticalMinerals #GoldExploration